°í·ÁÀÇ´ë ±è³²ÈÆ ±³¼ö(°í´ë¾È¾Ïº´¿ø ³»ºÐºñ³»°ú) |
¹è°æ
À۳⿡ ´ëÇÑ´ç´¢º´ÇÐȸ(KDA) 2021³â ´ç´¢º´ Áø·áÁöħ 7ÆÇÀÌ »õ·Ó°Ô Ãâ°£µÆ´Ù. 2019³â ´ç´¢º´ Áø·áÁöħ 6ÆÇ ÀÌÈÄ¿¡ °³Á¤µÈ °¡À̵å¶óÀÎÀ̹ǷΠ2019³â¿¡¼ 2021³â »çÀÌ ÃâÆÇµÈ »õ·Î¿î ÀÓ»óÀû ±Ù°Å¸¦ Ãæ½ÇÈ÷ ¹Ý¿µÇß´Ù. ±× µ¿¾È ´ç´¢º´½ÅÀåÁúȯÀÇ Ä¡·á ¹× °ü¸®¿¡ À־ ¿À·£ ±â°£ Ưº°ÇÑ º¯È°¡ ¾ø¾ú´Ù.
Á¦2Çü´ç´¢º´ ȯÀÚ¿¡¼ ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ACEI) ¹× ¾ÈÁö¿ÀÅÙ½ÅII¼ö¿ëüÂ÷´ÜÁ¦(ARB)ÀÇ ½ÅÀåÁúȯ ÁøÇà ¾ïÁ¦ÀÇ È¿°ú°¡ ¹ßÇ¥µÈ °ÍÀÌ 2000³â°æÀ̾ú´ø °ÍÀ» »ý°¢Çغ¸¸é ¹«·Á 20¿©³â°£ »õ·Î¿î Ä¡·áÁ¦°¡ ¾ø¾ú´Ù°í Çصµ °ú¾ðÀÌ ¾Æ´Ò °ÍÀÌ´Ù.
ÇÏÁö¸¸ 2015³â ÀÌÈÄ »õ·Î¿î ¾àÁ¦µéÀÇ ÀÓ»óÀû ±Ù°ÅµéÀÌ Ãß°¡µÇ¸é¼ ´ç´¢º´½ÅÀåÁúȯÀÇ Ä¡·á´Â ÀÏ´ë Àüȯ±â¸¦ ¸Â°í ÀÖ´Ù°í ÇÒ ¼ö ÀÖ´Ù. 2022³â 1¿ù¿¡´Â ¹Ì±¹´ç´¢º´ÇÐȸ(ADA) °¡À̵å¶óÀÎÀÇ ¾÷µ¥ÀÌÆ®°¡ ÀÖ¾ú´Ù. Àü¹ÝÀûÀÎ ±âÁ¶¿¡ ÀÖ¾î¼ ´ëÇÑ´ç´¢º´ÇÐȸ °¡À̵å¶óÀΰú Å« Â÷À̸¦ º¸ÀÌÁö ¾ÊÀ¸³ª, ¾àÁ¦ ¼±ÅÃÀÇ ±âÁØÀ̶óµçÁö »õ·Î¿î ¾àÁ¦ÀÇ ±Ç°í ¼öÁØ¿¡ ÀÖ¾î Â÷ÀÌ°¡ ³ª´Â ºÎºÐÀÌ Á¸ÀçÇÑ´Ù.
´ç´¢º´ ½ÅÀåÁúȯÀÇ Áø´Ü°ú ÃßÀû °Ë»ç
´ç´¢º´ ½ÅÀåÁúȯÀÇ Áø´ÜÀº ÀÌÀü°ú µ¿ÀÏÇÏ´Ù. »ç±¸Ã¼¿©°úÀ² 60mL/min/1.73§³ ¹Ì¸¸, ȤÀº ¾ËºÎ¹Î´¢°¡ ÀÖ´Â °æ¿ì¸¦ ´ç´¢º´ ½ÅÀåÁúȯÀ¸·Î Áø´ÜÇÑ´Ù. »ç±¸Ã¼¿©°úÀ²Àº Ç÷û Å©·¹¾ÆƼ´ÑÀ» ÀÌ¿ëÇÑ °ø½ÄÀ¸·Î °è»êÇϴµ¥, Chronic Kidney Disease-Epidemiology Collaboration(CKD-EPI)¹ýÀÌ ÀϹÝÀûÀ¸·Î ¼±È£µÈ´Ù. ¾ËºÎ¹Î´¢´Â ¹«ÀÛÀ§ ¼Òº¯¿¡¼ ÃøÁ¤µÈ ¾ËºÎ¹Î°ú Å©·¹¾ÆƼ´ÑÀÇ ºñ (UACR)¸¦ ÅëÇØ Áø´ÜÇÏ´Â °ÍÀ» ±Ç°íÇϸç UACRÀÌ 30mg/g ÀÌ»óÀÏ ¶§ ¾ËºÎ¹Î´¢°¡ ÀÖ´Ù°í ÆÇ´ÜÇÑ´Ù. ¼Òº¯¾ËºÎ¹Î¹è¼³ÀÇ º¯µ¿¼º ¶§¹®¿¡ 6°³¿ù µ¿¾È 3ȸÀÇ °Ë»ç¿¡¼ Àû¾îµµ 2ȸ ÀÌ»ó Áõ°¡µÅ ÀÖ¾î¾ß ¾ËºÎ¹Î´¢¶ó°í È®ÁøÇÑ´Ù. ¸ðµç ´ç´¢º´ ȯÀÚ¿¡¼ UACR°ú »ç±¸Ã¼¿©°úÀ²Àº ÃÖ¼Ò 1³â¸¶´Ù °Ë»çÇÏ´Â °ÍÀ» ±Ç°íÇÑ´Ù.
´ç´¢º´½ÅÀåÁúȯÀÇ ¾à¹° Ä¡·á
1) ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·Ð ½Ã½ºÅÛ ¾ïÁ¦Á¦
»ç±¸Ã¼¿©°úÀ² 60mL/min/1.73§³ ¹Ì¸¸À̰ųª UACR 300mg/g ÀÌ»óÀÇ ¾ËºÎ¹Î´¢°¡ ÀÖ´Â ´ç´¢º´ ȯÀÚÀÇ Ç÷¾Ð Ä¡·áÁ¦·Î ´ç´¢º´ ½ÅÀåÁúȯ ÁøÇà¿¡ ¾ïÁ¦È¿°ú°¡ ±Ô¸íµÈ ACEI ¶Ç´Â ARB°¡ ±Ç°íµÈ´Ù. Á» ´õ ³·Àº ¼öÁØÀÇ ¾ËºÎ¹Î´¢(UACR 30~300mg/g)¸¦ °¡Áø ȯÀÚ¿¡°Ô¼´Â ACEI³ª ARB°¡ ¾ËºÎ¹Î´¢ÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÑ´Ù°í ¹àÇôÁ³À¸³ª, ¸»±â½ÅÁúȯ ¹ß»ý ¾ïÁ¦ È¿°ú´Â ¸íÈ®ÇÏÁö ¾Ê´Ù. ¹Ý¸é ¾ËºÎ¹Î´¢ Á¸Àç ¿©ºÎ¿Í °ü°è¾øÀÌ Ç÷¾ÐÀÌ Á¤»óÀÎ ´ç´¢º´ ȯÀÚ¿¡¼´Â ACEI³ª ARB´Â ´ç´¢º´½ÅÀåÁúȯÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÏÁö ¸øÇØ ÀÏÂ÷¿¹¹æ ¸ñÀûÀ¸·Î´Â ±Ç°íµÇÁö ¾Ê´Â´Ù.
2) SGLT-2¾ïÁ¦Á¦
´ç´¢º´ ½ÅÀåÁúȯÀÇ »õ·Î¿î Áø·áÁöħ¿¡¼ °¡Àå Å« º¯È´Â SGLT-2¾ïÁ¦Á¦ »ç¿ë°ú °ü·ÃÇÑ °ÍÀÌ´Ù. EMPA-REG OUTCOME ¿¬±¸¿¡¼ È®ÀÎµÈ SGLT-2¾ïÁ¦Á¦ÀÇ ½ÅÀåÁúȯ ÁøÇà ¾ïÁ¦ÀÇ È¿°ú´Â DAPA-CKD ¿¬±¸¸¦ ÅëÇØ ´õ¿í °ø°íÇØÁ³À¸¸ç, À̸¦ ÅëÇØ ¸¸¼º½ÅÀåÁúȯÀÌ ÀÖ´Â Á¦2Çü´ç´¢º´ ȯÀÚ¿¡¼ SGLT-2¾ïÁ¦Á¦ÀÇ ¿ì¼±Àû »ç¿ëÀ» ±Ç°íÇÏ°Ô µÆ´Ù.
´ë±Ô¸ð ¹«ÀÛÀ§¹èÁ¤ ÀÓ»ó½ÃÇè ¹× ¸ÞŸºÐ¼®¿¡ ÀÇ°ÅÇÏ¿© Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÏ¿´À» ¶§, SGLT-2¾ïÁ¦Á¦´Â Á¦2Çü´¢º´ ȯÀÚ¿¡¼ ½ÅÀåÁúȯÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÏ´Â È¿°ú°¡ ÀÖÀ¸¸ç, ¾ËºÎ¹Î´¢ÀÇ ÁøÇà, »ç±¸Ã¼¿©°úÀ²ÀÇ ¾ÇÈ, ½Å´ëü¿ä¹ýÀÇ ½ÃÀÛ µî ´Ù¾çÇÑ ¼öÁØ¿¡¼ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î º¸ÀδÙ. ±Ù°Å°¡ µÇ´Â ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÌ ´ëºÎºÐ ½ÉÇ÷°üÁúȯÀÌ Àְųª, ½ÉÇ÷°üÁúȯÀÇ °íÀ§Ç豺, ȤÀº ¸¸¼º½ÅÀåÁúȯÀÌ ÀÖ´Â Á¦2Çü´ç´¢º´ ȯÀÚ¿´À¸¹Ç·Î ÇØ´ç ȯÀÚ±º¿¡¼ÀÇ ¿ì¼±Àû »ç¿ëÀ» °í·ÁÇÒ ¼ö ÀÖ´Ù.
SGLT-2¾ïÁ¦Á¦ »ç¿ëÀ» ±Ç°íÇÏ´Â »ç±¸Ã¼¿©°úÀ² ¼öÁØ°ú UACR ¼öÁØ¿¡ ´ëÇؼ´Â ADA¿Í KDA °¡À̵å¶óÀο¡ Â÷ÀÌ°¡ ÀÖ´Ù. EMPA-REG OUTCOME, CANVAS, DECLARE, DAPA-CKD ¿¬±¸¿¡¼ SGLT-2¾ïÁ¦Á¦ÀÇ Á¾ÇÕÀû ½ÅÀåÁ¾°áÁ¡¿¡ ´ëÇÑ È¿°ú´Â »ç±¸Ã¼¿©°úÀ² ¼öÁØ, UACR ¼öÁØ°ú °ü°è¾øÀÌ À̵æÀÌ ÀÖ´Â °ÍÀ¸·Î È®Àεưí, À̸¦ ¹ÙÅÁÀ¸·Î KDA °¡À̵å¶óÀο¡¼´Â »ç±¸Ã¼¿©°úÀ² 60mL/min/1.73§³ ¹Ì¸¸À̰ųª UACR 30mg/g ÀÌ»óÀÇ ¾ËºÎ¹Î´¢°¡ Àִ ȯÀÚ¿¡¼ SGLT-2¾ïÁ¦Á¦ »ç¿ëÀ» ±Ç°íÇÑ´Ù.
ADA´Â ¸¸¼º½ÅÀåÁúȯ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ DAPA-CKD ¹× CREDENCE ¿¬±¸¿¡ ³ôÀº ±Ù°Å ¼öÁØÀ» Àû¿ëÇØ, ÀÌ ¿¬±¸ÀÇ ´ë»óÀÚ¿´´ø »ç±¸Ã¼¿©°úÀ² 25mL/min/1.73§³ ÀÌ»ó, UACR 300mg/g ÀÌ»óÀÎ ´ç´¢º´ ½ÅÀåÁúȯ ȯÀÚ¿¡¼ SGLT-2¾ïÁ¦Á¦ÀÇ ¿ì¼±Àû »ç¿ëÀ» ±Ç°íÇÑ´Ù. µû¶ó¼ KDA °¡À̵å¶óÀο¡¼ SGLT2 ¾ïÁ¦Á¦ ±Ç°í ¹üÀ§°¡ ´õ ³ÐÀº °ÍÀ» ¾Ë ¼ö ÀÖ´Ù.
3) GLP-1¼ö¿ëüÀÛ¿ëÁ¦
SGLT-2¾ïÁ¦Á¦¿Í ¸¶Âù°¡Áö·Î GLP-1¼ö¿ëüÀÛ¿ëÁ¦ ¶ÇÇÑ ¿©·¯ ´ë±Ô¸ð ½ÉÇ÷°üÁúȯ ÀÓ»ó½ÃÇè¿¡¼ ½ÅÀå º¸È£ È¿°ú°¡ °üÂûµÈ ¹Ù ÀÖ´Ù. ÇÏÁö¸¸ SGLT-2¾ïÁ¦Á¦¿Í ´Þ¸® ½ÅÀåÁúȯ Á¾°áÁ¡À» ÀÏÂ÷Á¾°áÁ¡À¸·Î ÇÏ´Â Á÷Á¢ÀûÀÎ ¿¬±¸°¡ ¾ÆÁ÷ ¾øÀ¸¹Ç·Î ±Ù°Å ¼öÁØÀº ´Ù¼Ò ³·´Ù°í ÇÒ ¼ö ÀÖ´Ù. ¶ÇÇÑ ½ÅÀåÁúȯÁ¾°áÁ¡ÀÇ Á¤ÀÇ¿¡ °Å´ë´Ü¹é´¢ÀÇ ¹ß»ýÀÌ Æ÷ÇԵǾú°í, GLP-1¼ö¿ëüÀÛ¿ëÁ¦ÀÇ ½ÅÀ庸ȣȿ°ú´Â °Å´ë´Ü¹é´¢ ¹ß»ý ¾ïÁ¦ È¿°ú¿¡ ÀÇÁ¸ÀûÀ̾ú´Ù´Â ÇѰ踦 °®´Â´Ù. KDA °¡À̵å¶óÀο¡¼´Â ´ç´¢º´ ½ÅÀåÁúȯ ȯÀÚ¿¡¼ SGLT-2¾ïÁ¦Á¦ »ç¿ëÀÌ ¾î·Á¿î °æ¿ì, ȤÀº º¸´Ù Àû±ØÀûÀÎ Ç÷´ç°ÇÏ°¡ ÇÊ¿äÇÑ °æ¿ì Áö¼ÓÇü GLP-1¼ö¿ëüÀÛ¿ëÁ¦¸¦ 2Â÷ ¾àÁ¦·Î ±Ç°íÇß´Ù. ÇÏÁö¸¸ 2022 ADA °¡À̵å¶óÀο¡¼´Â ÁÖ ±Ç°í¾È¿¡ GLP-1¼ö¿ëüÀÛ¿ëÁ¦ÀÇ Á÷Á¢Àû ¾ð±ÞÀÌ ºüÁ³´Ù. ÇöÀç ¶Ç´Ù¸¥ GLP-1¼ö¿ëüÀÛ¿ëÁ¦ÀÎ ¼¼¸¶±Û·çŸÀ̵åÀÇ ´ë±Ô¸ð ÀÓ»ó½ÃÇè (FLOW¿¬±¸, ½ÅÀåÁ¾°áÁ¡À» ÀÏÂ÷ Á¾°áÁ¡À¸·Î ÁøÇàÇÏ´Â ÀÓ»ó½ÃÇè)ÀÌ ÁøÇà ÁßÀ̹ǷΠÀÌ ¿¬±¸ÀÇ °á°ú¸¦ ±â´Ù·Áº¼ ÇÊ¿ä°¡ ÀÖ°Ú´Ù.
4) ¹Ì³×¶öÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü ¾ïÁ¦Á¦(MRA)
2022 ADA °¡À̵å¶óÀο¡¼ ÁÖ¸ñÇÒ¸¸ÇÑ º¯È´Â ¹Ì³×¶öÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü ¾ïÁ¦Á¦ÀÎ Çdz׷¹³í(finerenone)¿¡ ´ëÇÑ ¾ð±ÞÀÌ´Ù. FIDELIO-DKD ¿¬±¸¿¡¼ Çdz׷¹³íÀÇ ½ÅÀåÁúȯ ÁøÇà ¾ïÁ¦ È¿°ú°¡ È®Àεưí, µû¶ó¼ ADA¿¡¼´Â ½ÅÀåÁúȯ ÁøÇàÀ» ¾ïÁ¦Çϱâ À§ÇØ SGLT-2¾ïÁ¦Á¦ ´ÙÀ½À¸·Î 2Â÷ ¾àÁ¦·Î¼ Çdz׷¹³íÀ» ±Ç°íÇß´Ù. ÇÏÁö¸¸ ÀÌ ¾àÁ¦´Â Çѱ¹¿¡ Ãâ½ÃµÇÁö ¾Ê¾Ò±â ¶§¹®¿¡ ±¹³» ȯÀÚµéÀ» ´ë»óÀ¸·Î ±Ç°íÇϱ⿡´Â ÇöÀç·Î¼´Â ¹«¸®°¡ ÀÖ´Ù.
°á·Ð
¾Õ¼ »ìÆ캻 ¹Ù¿Í °°ÀÌ ÃÖ±Ù¿¡ ¹ßÇ¥µÈ ´Ù¾çÇÑ ÀÓ»ó½ÃÇèÀÇ °á°úµé·Î ÀÎÇØ ´ç´¢º´ ½ÅÀåÁúȯÀÇ Áø·áÁöħ¿¡ °ý¸ñÇÒ ¸¸ÇÑ º¯È°¡ ÀÖ¾ú´Ù. ƯÁ¤ °è¿ ¾àÁ¦ÀÇ »ç¿ëÀÌ ½ÅÀåÁúȯ ÁøÇàÀ» ¾ïÁ¦ÇÑ´Ù´Â °ÍÀº ´ç´¢º´ Ä¡·á¿¡ ÀÖ¾î Æз¯´ÙÀÓÀÇ ÀüȯÀ̶ó°í ÇÒ ¸¸ÇÏ´Ù. ƯÈ÷ SGLT-2¾ïÁ¦Á¦´Â ±×µ¿¾È Ä¡·á°¡ ¾î·Æ´Ù°í ¾Ë·ÁÁø ´ç´¢º´ ½ÅÀåÁúȯÀÇ ÁøÇà ¾ïÁ¦¿¡ ´ëÇؼ ÀǹÌÀÖ´Â ÁøÀüÀ» º¸¿©Áá´Ù. ±×·¯³ª ¸ðµç ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÌ Áö±Ý±îÁö ¾Ë·ÁÁ³´ø ±âº» Ä¡·á(Ç÷¾Ð°ú Ç÷´ç, ÀÌ»óÁöÇ÷ÁõÀÇ Á¶Àý) À§¿¡ ¼¼¿öÁø ±Ù°Å¶ó´Â Á¡À» ´Ù½Ã ÇÑ ¹ø »ó±âÇÒ ÇÊ¿ä°¡ ÀÖ´Ù.
References
1. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
2. Brenner BM, Cooper ME, de Zeeuw D, W F Keane, W E Mitch, H H Parving, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
3. E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60.
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
5. Parving HH, Lehnert H, Brochner-Mortensen J, R Gomis, S Andersen, P Arner, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
6. Mauer M, Zinman B, Gardiner R, Samy Suissa, Alan Sinaiko, Trudy Strand, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
7. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Leanne Dyal, Ingrid Copland, Helmut Schumacher, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
8. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375:323-34.
9. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-57.
10. Heerspink HJL, Stef?nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-46.
11. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2021;6:148-158.
12. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-39.
13. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845-854.
14. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017;377:839-48.
15. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30.
16. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-85.
17. Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2018;6:859-69.
18. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:605-17.
THE MOST webmaster@mostonline.co.kr
<ÀúÀÛ±ÇÀÚ © THE MOST, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>
#´ëÇÑ´ç´¢º´ÇÐȸ#´ç´¢º´#´ç´¢º´¼º ½ÅÀåÁúȯ#·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·Ð ½Ã½ºÅÛ ¾ïÁ¦Á¦#SGLT-2¾ïÁ¦Á¦#GLP-1¼ö¿ëüÀÛ¿ëÁ¦#¹Ì³×¶öÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü ¾ïÁ¦Á¦